10 Best Online Weight Loss Programs of October 2026

Measured ranks #1 on this list with a score of 7.9/10 and plans from $119/mo. Scores weigh trust and safety, value, patient experience, product range and reputation.

Of the providers on this list, Collective has the lowest starting price at $17/mo (Annual Membership). Starting prices often rise with dose or after an intro period, so compare the ongoing price too.

Across the 109 providers we compared, starting prices range from $12 to $699.99 per month, with a median of $139.99. 68 of them run an intro offer or first-month discount.

By our category score: trust and safety (30%), value (25%), patient experience (20%), product range in this category (15%) and reputation (10%), with a small bonus for specialists. The full methodology is published on our methodology page.

Yes. Telehealth providers connect you with licensed clinicians who evaluate your BMI, health history, and goals — usually through an online intake, sometimes with a video visit. If you qualify, the prescription is sent to a partner pharmacy and shipped to you. Most programs require a BMI of 30+, or 27+ with a weight-related condition.

Brand-name GLP-1s like Wegovy and Zepbound are FDA-approved drugs made by Novo Nordisk and Eli Lilly. Compounded versions contain the same active ingredient but are prepared by compounding pharmacies and are not individually FDA-approved. Compounded is usually cheaper, though manufacturer self-pay pricing (roughly $149–349/month for Wegovy and $299–449/month for Zepbound, depending on form and dose) has narrowed the gap considerably. Oversight of compounded medication varies by pharmacy — which is why we score sourcing transparency in our trust dimension.

Usually not through cash-pay telehealth platforms — most operate outside insurance entirely. If you have coverage for weight loss medication, it's often cheaper to get a prescription through your own doctor and use insurance at a retail pharmacy. Cash-pay telehealth makes the most sense when insurance won't cover the medication.

In clinical trials, patients on semaglutide lost an average of 15–17% of body weight over about 16 months, and tirzepatide patients lost up to 22.5%. Individual results vary widely, and most patients regain a substantial portion after stopping, so a plan for maintenance matters as much as the medication.